首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 125 毫秒
1.
奥氮平治疗精神分裂症33例临床分析   总被引:10,自引:1,他引:9  
目的 评价奥氮平治疗精神分裂症的疗效及安全性。方法 以奥氮平治疗精神分裂症233例,疗程6周。疗铲评定采用阳性和阴性症状量表(PANSS),简明精神病评定量表(BPRS),临床总体印象量表(CGI-S)《不良 定采用不自主运动量表(AIMS)、Simpson-Angus量表(SAS)和副反应量表(TESS)。评定时间为治疗前及治疗后各周。结果痊愈55%,显产30%,进步12%,无效3%,BRPS总  相似文献   

2.
齐拉西酮与奥氮平治疗精神分裂症对照研究   总被引:1,自引:0,他引:1  
目的:探讨齐拉西酮与奥氮平治疗精神分裂症的疗效及安全性。方法:共59例精神分裂症,分别以齐拉西酮(30例)及奥氮平(29例)治疗。采用阳性与阴性症状量表(PANSS)、治疗中出现的症状量表(TESS)评定疗效及不良反应。结果:齐拉西酮组有效率为80.0%,显效率为63.3%,与奥氮平组相当,对阴性症状疗效优于奥氮平组。结论:齐拉西酮治疗精神分裂症疗效较好,不良反应较少。  相似文献   

3.
小剂量奥氮平治疗精神分裂症12例疗效分析   总被引:8,自引:1,他引:7  
目的 通过对奥氮平治疗精神分裂症疗效的分析,进一步了解奥氮平的特性。方法 入组对象12例(男女各6例),均符合CCCMD-ⅡR精神分裂症诊断标准,完成为期6周观察。奥氮平治疗剂量均5mg/日,在治疗前及治疗后1、2、4、6周分别评定PANSS、BPRS及TESS量表。结果 奥氮平总有效率为83.4%,显效率为66.7%,PANSS总分及各因子分,BPRS总分及各因子分治疗前后相比均有显著差异。副反  相似文献   

4.
奥氮平和利培酮治疗精神分裂症临床对照研究   总被引:1,自引:0,他引:1  
目的比较奥氮平和利培酮对精神分裂症的治疗效果和安全性。方法以奥氮平与利培酮对120例精神分裂症患者进行为期6周的对照治疗,采用阳性和阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)评定副反应。结果奥氮平组显效率76.7%,有效率95%;利培酮组显效率76.7%。有效率93%。奥氮平的主要副反应为嗜睡,利培酮的主要副反应为锥体外系反应。结论两药治疗精神分裂痘均有良好疗效.且安全性较高。  相似文献   

5.
利培酮治疗精神分裂症的临床验证   总被引:6,自引:1,他引:5  
为验证利培酮治疗精神分裂症的有效性和安全性,对20例按DSM—Ⅳ诊断的精神分裂症住院患者进行治疗,剂量2~6mg/d,疗程8周。以阳性症状和阴性症状量表(PANSS)评定疗效,以锥体外系症状评定量表(ESRS)评定锥体外系反应(EPS)。治疗结束时,显效率(痊愈+显著进步)为70%,有效率90%,利培酮治疗起效时间为1周。提示利培酮是一种对精神分裂症阳性症状和阴性症状均有一定疗效的抗精神病药物。  相似文献   

6.
齐拉西酮与奥氮平治疗首发精神分裂症对照研究   总被引:3,自引:0,他引:3  
目的:探讨齐拉西酮与奥氮平治疗首发精神分裂症的临床疗效与安全性。方法:将64例首发精神分裂症患者随机分为齐拉西酮组32例与奥氮平组32例,治疗8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:齐拉西酮组总有效率为84.4%,奥氮平组为87.5%,两组差异无显著性(P〉0.05)。齐拉西酮组主要不良反应是失眠,奥氮平组是体质量增加和血糖升高。结论:齐拉西酮与奥氮平治疗首发精神分裂症均有良好疗效,2药不良反应均较轻。  相似文献   

7.
目的 探讨与氯氮平对慢性难治性精神分裂症疗效有关的5-羟色胺2A(5-HT2A)受体基因的基因型及其他相关因素。方法 抽取104例慢性难治性精神分裂症患者,给予氯氮平≥400mg/d治疗2个月。治疗前后用阴性和阳性症状量表(PANSS)评定氯氮平疗效,按PANSS的减分率≥30%和≤30%将氯氮平治疗的患者分为有效组和无效组,用聚合酶链反应扩增及限制性片段长度多态性(PCR-RFLPs)技术测定患  相似文献   

8.
目的探讨奥氮平治疗精神分裂症的疗效和安全性。方法将60例精神分裂症患者随机分为研究组和对照组,每组各30例。研究组应用奥氮平治疗,起始剂量5mg/d,第2天增至10mg/d,最大剂量≤20mg/d;对照组应用氯氮平治疗,起始剂量50mg/d,1周内递增到300mg/d,最大剂量≤600mg/d。疗程均为8周。分别于治疗前及治疗第1、2、4、8周末,采用阳性和阴性症状量表评定临床疗效,副反应量表评定不良反应。结果奥氮平有效率76.66%,氯氮平有效率70%;奥氮平在阴性症状方面优于氯氮平,两组比较差异有显著性(P〈0.05),奥氮平组主要不良反应有轻度头昏、瞌睡、体质量增加等。结论奥氮平是一种安全有效的抗精神病药物,对改善急性期精神症状以及阴性症状方面,优于氯氮平。  相似文献   

9.
口服利培酮治疗精神分裂症   总被引:14,自引:1,他引:13  
为验证利培酮治疗精神分裂症的疗效和安全性,对20例精神分裂症住院患者给予利培酮4~8mg/d治疗,疗程8周,以阳性和阴性症状量表(PANSS)、大体评定量表(GAS)和临床总体印象量表(CGI)评定疗效,以锥体外系副反应量表(ESRS)和不良反应量表(TESS)评定药物不良反应。结果显示,治疗结束时显效率为90%。利培酮的起效时间在10天左右,仅有轻度的锥体外系副反应和失眠。提示利培酮对精神分裂症的阳性和阴性症状都有良好的疗效,且安全性较高  相似文献   

10.
目的比较奎硫平与奥氮平对精神分裂症患者的疗效及生活质量的影响。方法对60例精神分裂症患者,随机分为奎硫平组(30例)与奥氮平组(30例)治疗,疗程12周。分别于治疗前、4周、8周、12周末,采用阳性与阴性症状量表(PANSS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应,于治疗前和12周末采用生活质量综合评定问卷(GQOLI-74)评定生活质量。结果两组均有显著疗效,奎硫平组与奥氮平组均可显著提高生活质量。两组间比较无统计学意义(P〉0.05)。奎硫平组主要不良反应为嗜睡,但两组间比较无显著差异;奥氮平组主要不良反应为体重增加、血糖升高,两组有统计学意义。结论奎硫平与奥氮平对精神分裂症疗效好,不良反应较少,均可提高患者生活质量。  相似文献   

11.
奥氮平治疗精神分裂症70例临床分析   总被引:19,自引:2,他引:17  
目的 了解奥氮平治疗精神分裂症的疗效和安全性。方法 对70例精神分裂症病人用奥氮平治疗6周,以阳性和阴性症状量表(PANSS)和简明精神病评定量表(BPRS)评定临床疗效。以副反应量表(TESS)和实验室监测评价安全性。于基线时、实验第1、2、4、6周末分别评定各量表。统计方法为描述性分析和配对t检验。结果 共收集有效病例70例,其中基本痊愈24.2%(17/70),显著进步37.1%(26/70),好转21.4%(15/70)和无效17.1%(12/70)。BPRS总分、PANSS总分、PANSS各分量表分治疗前后比较均有显著性差异(P<0.001)。奥氮平对阳性、阴性症状以及一般精神病症状均有良好疗效。常见副反应为胆碱能作用、嗜睡、体重增加和一过性肝酶升高等。结论 奥氮平是一种安全有效、服用方便的新型抗精神病药物,病人的服药依从性好。  相似文献   

12.
目的:探讨国产奥氮平治疗精神分裂症的临床疗效及其对生活质量的影响。方法:将64例精神分裂症患者随机分为奥氮平组和氯氮平组治疗8周,于治疗前后用阳性与阴性症状量表(PAN-SS)和治疗中出现的症状量表(TESS)评定其疗效和不良反应,生活质量量表(GQOLI-74)分析患者的生活质量。结果:奥氮平组与氯氮平组疗效差异无显著性(P>0.05);奥氮平组生活质量各维度改善均优于氯氮平组。结论:国产奥氮平和氯氮平对于精神分裂症的疗效相当,对提高精神分裂症患者的生活质量明显优于氯氮平。  相似文献   

13.
目的 观察奥氮平对精神分裂症患者认知功能障碍的疗效及其对患者糖、脂代谢影响。方法 将60例接受单一奥氮平治疗的精神分裂症患者,采用修订韦氏记忆量表(WMS-RC)评定记忆功能;威斯康星卡片分类测验(WCST)评定执行功功能;PANSS量表评定精神症状;并检测血糖、胆固醇和甘油三脂,分别在治疗前、治疗8周末各进行1次。结果 经过8用的奥氮平治疗后,记忆商数显著提高(P〈0.001);威斯康星卡片分类测验的总测验次数、持续错误数及随机错误数均显著下降(P〈0,05或P〈0.01);并且奥氮平对记忆功能、执行功能的改善与阳性症状、阴性症状的下降呈显著正相关。治疗8周末血糖、胆固醇和甘油三脂水平均显著高于治疗前(P〈0.05或P〈0.01)。结论 奥氮平能有效的改善精神分裂症患者的认知功能障碍,但应重视其对患者糖脂代谢的副作用.  相似文献   

14.
奥氮平与氯氮平治疗难治性精神分裂症对照研究   总被引:8,自引:0,他引:8  
目的评价奥氮平治疗难治性精神分裂症的疗效及安全性。方法将64例难治性精神分裂症患者随机分为研究组和对照组,分别予以奥氮平和氯氮平治疗8周,采用PANSS量表和TESS量表评定疗效和不良反应。结果奥氮平组治疗前后PANSS减分率为39.3%,有效率为72.8%;氯氮平组治疗前后PANSS减分率为36.6%,有效率为59.4%。奥氮平组未见严重的不良反应。结论奥氮平与氯氮平治疗难治性精神分裂症均有良好疗效,奥氮平的副作用小,病人依从性好。  相似文献   

15.
BACKGROUND: This analysis compares the efficacy of risperidone and olanzapine in controlling negative and positive symptoms of chronic psychosis in older patients. METHOD: Post hoc assessments were made in a subset of risperidone-treated (N = 19) and olanzapine-treated (N = 20) older patients (aged 50 to 65 years) from a large international, multicenter, parallel, double-blind, 28-week study of patients aged 18 to 65 years (N = 339) randomly assigned to receive risperidone (4-12 mg/day) or olanzapine (10-20 mg/day). Assessments were made using repeated-measures analysis. RESULTS: At both 8 weeks and 28 weeks, the magnitude of changes in Positive and Negative Syndrome Scale (PANSS) positive symptom subscale scores did not differ between treatment groups (8 weeks: risperidone, -6.5; olanzapine, -6.8, p = .866; 28 weeks: risperidone, -6.5; olanzapine, -7.0; p = .804). However, by the 8-week timepoint, olanzapine had reduced PANSS negative subscale scores significantly more than risperidone (-8.8 vs. -4.9, p = .032). By the 28-week endpoint, olanzapine had continued to maintain significantly greater reduction in baseline-to-endpoint PANSS negative scores (-8.1 vs. -3.5, p = .032) and led to significantly greater reduction in scores on the Scale for the Assessment of Negative Symptoms (SANS) dimensions of affective flattening (-5.2 vs. -0.6, p = .033) and alogia (-3.8 vs. -0.3, p = .007). Patients in the olanzapine treatment group also demonstrated numerically greater reduction of both SANS summary (-3.7 vs. -1.0, p = .078) and SANS composite scores (-14.1 vs. -4.1, p = .075). CONCLUSION: These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms. However, olanzapine appears to be more efficacious in maintaining control over negative symptoms.  相似文献   

16.
奥氮平与利培酮治疗青少年首发精神分裂症对照研究   总被引:4,自引:2,他引:2  
目的比较奥氮平与利培酮治疗青少年首发精神分裂症的疗效和安全性。方法对60例青少年期首发精神分裂症患者随机分为两组,分别给予奥氮平与利培酮治疗8周。于治疗前及治疗后1、2、6、8周末进行阳性和阴性症状量表(PANSS)及副反应量表(TESS)评定。结果奥氮平与利培酮总的疗效无显著性差异,均能快速起效,PANSS总分比较治疗第1周与第2周末奥氮平组显著低于利培酮组,利培酮组锥体外系反应显著多于奥氮平组。结论奥氮平与利培酮均是治疗首发青少年精神分裂症安全有效的非典型抗精神病药物,可根据患者的不同情况分别选择。  相似文献   

17.
目的观察奥氮平合并氯氮平治疗男性以阴性症状为主的难治性精神分裂症的疗效以及安全性。方法对43例男性原服用氯氮平且以阴性症状为主的难治性精神分裂症患者合并奥氮平5~20mg/d治疗8周,同时于2周内将氯氮平减量且氯氮平剂量2周后不再变化,并于合并治疗前及后2周、4周、8周评定阳性症状与阴性症状量表(PANSS)、副反应量表(TESS)。结果合并奥氮平治疗后2周、4周、8周末PANSS总分和TESS评分较合并前有明显差异。结论奥氮平合并氯氮平对于男性难治性精神分裂症患者的阴性症状有明显的改善,副反应也有减少。  相似文献   

18.
BACKGROUND: Olanzapine is an atypical antipsychotic that has efficacy in adults with psychotic disorders. This preliminary study examined the effectiveness of olanzapine in adolescents with schizophrenia or its related conditions. METHOD: Adolescents aged 12-17 years (inclusive) with a diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder were enrolled in this 8-week, open-label, outpatient study. The Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), and the Children's Global Assessment Scale (CGAS) were administered as outcome measures. Extrapyramidal side effects were assessed at each visit. Olanzapine was initiated at a dose of 2.5 mg/day and could be increased to a maximum total daily dose of 20 mg. RESULTS: Sixteen participants with a mean age of 13.8 (SD = 1.5) years were treated. Significant improvements were found in the PANSS, CGI severity, and CGAS scores. Reductions in both positive and negative symptoms were found. Increased appetite and sedation were the most frequently reported side effects. Two subjects required treatment for extrapyramidal side effects. CONCLUSIONS: Psychotic symptoms significantly improved during study. Overall, olanzapine was well tolerated. Future studies are needed to confirm these findings, to assess long-term treatment outcomes, and to compare the effectiveness of olanzapine with that of other antipsychotics.  相似文献   

19.
BACKGROUND: The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications. METHOD: Data were collected between July 1, 2001, and October 25, 2002. The study population included patients from clinics, hospitals, and physicians' offices. After a 4-week run-in period, symptomatically stable patients with schizophrenia (DSM-IV) who had been taking haloperidol (N = 46), quetiapine (N = 45), or olanzapine (N = 50) received 25 mg of long-acting risperidone. The oral antipsychotics were continued for 3 weeks after the first injection of long-acting risperidone. Injections were administered every 2 weeks at 25 mg up to a maximum dose of 50 mg for 12 weeks in this multicenter, open-label study. RESULTS: Long-acting risperidone was well tolerated. Of the 141 patients who participated in the study, the most frequently reported adverse events were insomnia (16%), headache (15%), psychosis (11%), and agitation (11%). The mean increase in body weight was 0.4 kg. No other clinically relevant laboratory abnormalities or significant electrocardiogram changes were observed during the 12-week treatment. Extrapyramidal Symptom Rating Scale total scores were reduced during treatment with long-acting risperidone. Improvements in symptoms of schizophrenia were observed with long-acting risperidone at week 4 and continued through the 12-week treatment with significant reductions in total Positive and Negative Syndrome Scale (PANSS) scores at week 8 (-2.5, p <.01) and week 12 (-3.9, p <.001). At endpoint, 37% (50/135) of these stable patients were rated as clinically improved (> or = 20% decrease in PANSS total scores). CONCLUSIONS: Switching treatment from oral antipsychotics to long-acting risperidone without an intervening period of oral risperidone was safe and well tolerated. Long-acting risperidone also significantly reduced the severity of symptoms in these stable patients with schizophrenia.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号